All articles by Srivani Venna

Srivani Venna

UK’s NICE recommends Pfizer’s rimegepant to treat migraine

Up to 145,000 people in England will have the option to choose this treatment.

ImmunoForge expands agreement with Duke University for drug development

Duke University will use ELP platform technology for the development of new anticancer drugs.

KSQ and Takeda expand partnership for new tumour-intrinsic targets

KSQ will receive future payments of up to $510m upon achieving all milestones during the agreement period.

Formosa, AimMax submit NDA to FDA for new pain therapy

APP13007 is an aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate.

Boehringer receives breakthrough therapy designation for spesolimab

The US FDA and China’s NMPA granted the designations based on topline data from the EFFISAYIL 2 trial.

Plus Therapeutics and PPS expand partnership for cGMP drug production

Rhenium (186Re) obisbemeda has been formulated for safe delivery of highly targeted high dose radiation in CNS tumours.

Cartherics grants licence for CTH-004 to Shunxi

CTH-004 is an autologous CAR-T cell product developed to treat several solid tumours including ovarian cancer.

mRNA vaccine for cancer along with Keytruda obtains PRIME designation

The PRIME regulatory mechanism provides support for the development of medicines that target an unmet medical need.

UK’s NICE recommends AstraZeneca’s olaparib to treat cancer types

The latest decision by NICE reverses its earlier draft decision not to recommend olaparib for adults.

Biotheryx and Incyte sign agreement to develop protein degraders for oncology

Biotheryx will receive up to $347m in potential future regulatory and commercial milestone payments from Incyte.